Live feed08:00:00·1hPRReleasevia QuantisnowSCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)ByQuantisnow·Wall Street's wire, on your screen.SCYX· SCYNEXIS Inc.Health Care
